Public Profile

Alfasigma S.p.A.

Alfasigma S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and Asia. Founded in 2015 through the merger of Alfa Wassermann and Sigma-Tau, the company has quickly established itself as a leader in the development and marketing of prescription medicines, particularly in the fields of gastroenterology, central nervous system disorders, and cardiovascular health. Alfasigma's core products, including innovative treatments and generics, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, such as expanding its global footprint and enhancing its research capabilities. With a strong market position and a focus on patient-centric solutions, Alfasigma continues to make strides in improving health outcomes worldwide.

DitchCarbon Score

How does Alfasigma S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Alfasigma S.p.A.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.

17%

Let us know if this data was useful to you

Alfasigma S.p.A.'s reported carbon emissions

Alfasigma S.p.A., headquartered in Italy, currently does not have publicly available carbon emissions data or specific reduction targets. As a company operating in the pharmaceutical industry, Alfasigma is likely aware of the growing importance of sustainability and climate commitments. While no specific initiatives or targets have been disclosed, the industry is increasingly focused on reducing carbon footprints and enhancing environmental responsibility. Alfasigma's future climate commitments may align with these industry trends, reflecting a broader commitment to sustainability and climate action.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Alfasigma S.p.A.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Alfasigma S.p.A. is in IT, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Alfasigma S.p.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

i-STAT Corp.

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 months ago
DitchCarbon Score

Celltrion

KR
Research and development services (73)
Updated about 15 hours ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Organon Pharmaceuticals Usa Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

EA Pharma Co., Ltd

JP
Updated about 15 hours ago

Bms

US
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers